Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXO ALX Oncology	$0.54 +5.9%	$0.72	$0.46 ▼ $17.83	$28.83M	1.2	992,376 shs	390,152 shs
GDTC CytoMed Therapeutics	$2.37 -0.4%	$2.50	$1.20 ▼ $4.05	$25.93M	-0.26	77,837 shs	20,982 shs
JAGX Jaguar Health	$12.24 +2.1%	$8.72	$4.02 ▼ $540.00	$8.25M	1.1	43,061 shs	224,759 shs
TPST Tempest Therapeutics	$7.11 -3.1%	$9.10	$5.35 ▼ $49.27	$25.02M	-2.34	158,473 shs	64,542 shs

20 Stocks to Sell Now

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXO ALX Oncology	-3.83%	-13.98%	-22.15%	-65.07%	-96.99%
GDTC CytoMed Therapeutics	-0.62%	+2.13%	+6.97%	-6.45%	+8.62%
JAGX Jaguar Health	+12.37%	+96.56%	+139.80%	-46.11%	-96.16%
TPST Tempest Therapeutics	-6.26%	-3.17%	-26.87%	-37.06%	-83.59%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALXO ALX Oncology	2.5269 of 5 stars	3.4	2.0	1.0	3.3	1.3
GDTC CytoMed Therapeutics	2.1515 of 5 stars	3.5	4.0	3.0	0.0	0.0
JAGX Jaguar Health	0.1797 of 5 stars	0.0	2.0	2.4	0.0	0.0
TPST Tempest Therapeutics	2.3407 of 5 stars	3.3	5.0	2.3	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALXO ALX Oncology	2.71	Moderate Buy	$4.14	666.67% Upside
GDTC CytoMed Therapeutics	3.00	Buy	$5.00	110.97% Upside
JAGX Jaguar Health	0.00	N/A	N/A	N/A
TPST Tempest Therapeutics	2.50	Moderate Buy	$30.00	321.94% Upside

Current Analyst Ratings Breakdown

Latest JAGX, ALXO, TPST, and GDTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/10/2025	TPST Tempest Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$16.00 ➝ $16.00
4/10/2025	TPST Tempest Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Outperform ➝ Sector Perform	$7.00 ➝ $9.00
3/28/2025	TPST Tempest Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$169.00 ➝ $91.00
3/28/2025	TPST Tempest Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$611.00 ➝ $208.00
3/7/2025	ALXO ALX Oncology	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$3.00 ➝ $1.50
3/7/2025	ALXO ALX Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/6/2025	ALXO ALX Oncology	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$8.00 ➝ $9.00
3/6/2025	ALXO ALX Oncology	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$2.00 ➝ $3.00

(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALXO ALX Oncology	N/A	N/A	N/A	N/A	$3.81 per share	N/A
GDTC CytoMed Therapeutics	N/A	N/A	N/A	N/A	$0.78 per share	N/A
JAGX Jaguar Health	$11.69M	0.71	N/A	N/A	$4.02 per share	3.04
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	$1.39 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALXO ALX Oncology	-$160.80M	-$2.60	N/A	N/A	N/A	N/A	-93.02%	-70.67%	5/8/2025 (Estimated)
GDTC CytoMed Therapeutics	-$3.13M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
JAGX Jaguar Health	-$41.30M	N/A	0.00	N/A	N/A	-360.13%	-326.62%	-67.02%	5/13/2025 (Estimated)
TPST Tempest Therapeutics	-$29.49M	-$19.51	N/A	N/A	N/A	N/A	-187.44%	-82.61%	5/8/2025 (Estimated)

Latest JAGX, ALXO, TPST, and GDTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	JAGX Jaguar Health	-$18.50	N/A	N/A	N/A	$3.29 million	N/A
5/8/2025	Q1 2025	ALXO ALX Oncology	-$0.53	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	TPST Tempest Therapeutics	-$0.31	N/A	N/A	N/A	N/A	N/A
3/27/2025	Q4 2024	TPST Tempest Therapeutics	-$3.12	-$4.03	-$0.91	-$0.31	N/A	$0.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALXO ALX Oncology	N/A	N/A	N/A	N/A	N/A
GDTC CytoMed Therapeutics	N/A	N/A	N/A	N/A	N/A
JAGX Jaguar Health	N/A	N/A	N/A	N/A	N/A
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALXO ALX Oncology	0.07	4.82	4.82
GDTC CytoMed Therapeutics	0.04	21.54	N/A
JAGX Jaguar Health	1.65	1.84	1.36
TPST Tempest Therapeutics	N/A	1.69	1.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALXO ALX Oncology	97.97%
GDTC CytoMed Therapeutics	0.04%
JAGX Jaguar Health	12.04%
TPST Tempest Therapeutics	22.52%

Insider Ownership

Company	Insider Ownership
ALXO ALX Oncology	33.40%
GDTC CytoMed Therapeutics	N/A
JAGX Jaguar Health	0.38%
TPST Tempest Therapeutics	4.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALXO ALX Oncology	40	53.40 million	35.13 million	Optionable
GDTC CytoMed Therapeutics	N/A	10.94 million	N/A	Not Optionable
JAGX Jaguar Health	50	674,000	11.80 million	No Data
TPST Tempest Therapeutics	20	3.52 million	41.59 million	Optionable

JAGX, ALXO, TPST, and GDTC Headlines

Recent News About These Companies

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

April 28 at 4:16 PM | globenewswire.com

Dual EP2/EP4 Antagonist Designated Orphan Drug for Familial Adenomatous Polyposis

April 25, 2025 | empr.com

Cash-strapped Bay Area biotech company lays off all but 5 employees

April 24, 2025 | msn.com

Tempest Therapeutics: FDA Grants Orphan Drug Designation To TPST-1495

April 23, 2025 | nasdaq.com

Tempest Therapeutics Receives FDA Orphan Drug Designation for TPST-1495 to Treat Familial Adenomatous Polyposis

April 23, 2025 | nasdaq.com

Tempest Therapeutics

April 22, 2025 | thepharmaletter.com

Tempest Therapeutics stock rises on FDA Orphan Drug Designation

April 21, 2025 | in.investing.com

Tempest lays off 80% of workforce to ride out cash crunch

April 21, 2025 | fiercebiotech.com

Tempest Therapeutics announces FDA granted ODD to TPST-1495

April 21, 2025 | markets.businessinsider.com

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

April 21, 2025 | globenewswire.com

Scotiabank Reiterates Sector Perform Rating for Tempest Therapeutics (NASDAQ:TPST)

April 12, 2025 | marketbeat.com

HC Wainwright Reiterates "Neutral" Rating for Tempest Therapeutics (NASDAQ:TPST)

April 12, 2025 | marketbeat.com

Scotiabank Downgrades Tempest Therapeutics (TPST)

April 11, 2025 | msn.com

Tempest Therapeutics downgraded to Sector Perform from Outperform at Scotiabank

April 10, 2025 | markets.businessinsider.com

Tempest Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

April 10, 2025 | markets.businessinsider.com

Tempest hits funding block for Phase III liver cancer drug-in-waiting

April 10, 2025 | finance.yahoo.com

Tempest, weathering stormy capital markets, hunts for partners for liver cancer drug

April 10, 2025 | fiercebiotech.com

Tempest to explore alternatives to advance promising pipeline

April 10, 2025 | thepharmaletter.com

Tempest Therapeutics downgraded at Scotiabank as amezalpat finds no suitors

April 10, 2025 | markets.businessinsider.com

TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up

April 10, 2025 | zacks.com

Tempest Therapeutics to explore strategic alternatives

April 10, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JAGX, ALXO, TPST, and GDTC Company Descriptions

ALX Oncology NASDAQ:ALXO

$0.54 +0.03 (+5.88%)

As of 04:00 PM Eastern

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

CytoMed Therapeutics NASDAQ:GDTC

$2.37 -0.01 (-0.42%)

As of 02:19 PM Eastern

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.

Jaguar Health NASDAQ:JAGX

$12.24 +0.25 (+2.09%)

As of 04:00 PM Eastern

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Tempest Therapeutics NASDAQ:TPST

$7.11 -0.23 (-3.13%)

As of 04:00 PM Eastern

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time